Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia. - Wikidata - wikimedia - TriplyDB

Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia.

Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q35110582

about

Drugs under preclinical and clinical study for treatment of acute and chronic lymphoblastic leukemia New developments in the treatment of chronic lymphocytic leukemia: role of obinutuzumab New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.

P2860

Q26744365-FCD5CF26-E531-41AF-A2D2-00987457B1EC Q26801292-5C093A73-8AE1-4195-BBBB-5F791D09691D Q47221234-5E8ABBE9-C9F0-407B-A033-5DF9FA235EBA

P2860

Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q35110582

description

2015 nî lūn-bûn

@nan

2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Clinical role of obinutuzumab ...... chronic lymphocytic leukemia.

@ast

Clinical role of obinutuzumab ...... chronic lymphocytic leukemia.

@en

type

label

Clinical role of obinutuzumab ...... chronic lymphocytic leukemia.

@ast

Clinical role of obinutuzumab ...... chronic lymphocytic leukemia.

@en

prefLabel

Clinical role of obinutuzumab ...... chronic lymphocytic leukemia.

@ast

Clinical role of obinutuzumab ...... chronic lymphocytic leukemia.

@en

P1433

Q35110582-4A79EE3B-8E52-40A9-A3D8-FDA912F799A1

P1476

Q35110582-A8696D29-4C45-4819-8268-1661233E16DD

P2093

Q35110582-31E6E5E2-B356-41CB-8EA1-BC5930718F1B

Q35110582-A488E14A-D905-403C-A9D7-5762DA57F0EF

P2860

Q35110582-06D66666-DCCF-424D-8FDA-A6E3F17DFCF9

Q35110582-0A5B2EF8-8014-42BB-9D31-0CF397DBFFDB

Q35110582-0CE8F97C-EDCD-4C2B-B855-519F8031C476

Q35110582-11476B6E-86DB-4CFF-8215-21D2131A5812

Q35110582-134133B2-A5A7-4E96-A613-069AB4BAAB96

Q35110582-20DBB961-F2AF-4BF7-900E-90A8E79DBDD1

Q35110582-24C791E6-6FC1-4513-A064-868C5FC1001A

Q35110582-25C081A1-4A67-4E9E-B70A-B427A8AFA986

Q35110582-3B41B321-28A3-4817-BBCE-4ADD7DEEF4C4

Q35110582-3F713049-825C-4FB1-8FCC-E1FA0E4A4679

P304

Q35110582-5D211318-0AD3-46A8-82B6-6A3FBEEDFAD9

P31

Q35110582-43B14101-2246-4552-A380-DD9FCB5E8F94

P356

Q35110582-B7C41C56-887F-4979-A823-2A8715D11E40

P478

Q35110582-144EDC50-1D60-4CD4-8921-AFF120E0B78A

P577

Q35110582-90E3C62E-722F-4208-B83E-6C95DA2BCEE0

P5875

Q35110582-F95A1C2E-A3A1-44DE-9D9C-0EC5457C9866

P698

Q35110582-FE6A62A0-BE52-4D75-928E-CEF8AD8535A1

P921

Q35110582-2E14B507-202C-416B-8CAC-F1A8F4C14FB3

Q35110582-B23C639B-9B7D-44D8-861A-7BB97DF799A1

P932

Q35110582-889188EF-7E7B-49F8-96BC-B08B55CE0DDF

P356

P1433

Biologics: Targets and Therapy

P1476

Clinical role of obinutuzumab ...... chronic lymphocytic leukemia.

@en

P2093

Carolyn Owen

http://www.w3.org/2001/XMLSchema#string

Sonia Cerquozzi

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies

Cancer statistics, 2013

Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia.

Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving.

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies.

Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study.

Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions & clinical results in refractory CLL.

Obinutuzumab: a novel anti-CD20 monoclonal antibody for previously untreated chronic lymphocytic leukemia.

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

P304

13-22

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/BTT.S61600

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273156492

http://www.w3.org/2001/XMLSchema#string

P698

25733804

http://www.w3.org/2001/XMLSchema#string

P921

P932

4337412

http://www.w3.org/2001/XMLSchema#string